Upload Button Icon Add office photos
filter salariesFilter salaries by

Nucleon Therapeutics CTA salaries in India

Annual salary range
Select experience
₹2.9 Lakhs - ₹3.7 Lakhs
Low Confidence
info icon
Low confidence means that this average salary is based on data that was reported by very few people.
Avg. annual salary (AmbitionBox Estimate)
tooltip
This is an estimate of the average salary for this position. The actual salary may differ.
unlock blur

Monthly In-hand Salary

unlock blur

Interested in this particular role?

Last Updated: 26 Aug 2024

Companies similar to Nucleon Therapeutics for CTA

Company name Avg Annual Salary Open Jobs
Logo
TCS CTA Salary

2 - 5 years exp. (4 salaries)

unlock blur

₹3 L/yr - ₹3.3 L/yr

arrow icon 8% less
Logo
KlinEra Corporation CTA Salary

0 - 4 years exp. (6 salaries)

unlock blur

₹1 L/yr - ₹3.2 L/yr

arrow icon 46% less
Logo
IQVIA CTA Salary

1 - 3 years exp. (6 salaries)

unlock blur

₹4 L/yr - ₹5 L/yr

arrow icon 41% more
Logo
JSS Medical Research CTA Salary

1 - 3 years exp. (5 salaries)

unlock blur

₹3.3 L/yr - ₹4 L/yr

arrow icon 13% more
Logo
Royal Enfield CTA Salary

1 - 4 years exp. (4 salaries)

unlock blur

₹2.1 L/yr - ₹2.8 L/yr

arrow icon 32% less
CTA salary at Nucleon Therapeutics ranges between ₹2.9 Lakhs to ₹3.7 Lakhs per year for employees with 3 years of experience. Salary estimates are based on 1 latest salaries received from various employees of Nucleon Therapeutics.

Nucleon Therapeutics CTA Salary FAQs

How the salary growth look like for a CTA at Nucleon Therapeutics in India?
The salary growth for a CTA at Nucleon Therapeutics depends on factors such as experience, performance, and promotions. On average, a CTA can expect the following growth trajectory at Nucleon Therapeutics:

Experience Average Salary Range
3 years ₹2.9 Lakhs to ₹3.7 Lakhs per year
and so on.

Tell us how to improve this page.

Nucleon Therapeutics CTA salary in India ranges between ₹2.9 Lakhs to ₹3.7 Lakhs. This is an estimate based on latest salaries received from employees of Nucleon Therapeutics.